Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 134.9% in January

Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 273,000 shares, an increase of 134.9% from the December 31st total of 116,200 shares. Approximately 6.3% of the company’s shares are sold short. Based on an average trading volume of 242,400 shares, the days-to-cover ratio is presently 1.1 days.

Vivos Therapeutics Stock Down 7.1 %

Shares of VVOS stock traded down $0.30 on Thursday, hitting $3.94. The stock had a trading volume of 262,361 shares, compared to its average volume of 321,606. Vivos Therapeutics has a one year low of $1.91 and a one year high of $7.74. The business has a 50 day moving average price of $4.46 and a 200 day moving average price of $3.29. The company has a market cap of $19.07 million, a PE ratio of -0.69 and a beta of 7.51.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Alliance Global Partners decreased their price objective on shares of Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 19th. Ascendiant Capital Markets reiterated a “buy” rating and issued a $6.60 price target on shares of Vivos Therapeutics in a report on Wednesday, November 20th.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.